



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/082,772	02/25/2002	Peter Droge	DEBE:008US	4391
7590 12/24/2008 Steven L. Highlander FULBRIGHT & JAWORSKI L.L.P. Suite 2400 600 Congress Avenue, Austin, TX 78701				
EXAMINER NGUYEN, QUANG				
ART UNIT		PAPER NUMBER		
1633				
MAIL DATE		DELIVERY MODE		
12/24/2008		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Art Unit: 1633



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/082,772

Filing Date: February 25, 2002

Appellant(s): DROGE ET AL.

Steven L. Highlander, Reg. No. 37,642  
For Appellant

**EXAMINER'S ANSWER**

This Examiner's Answer will replace the Examiner's Answer dated 08/05/2008, and in response to the Reply Brief filed on 10/06/2008. This is necessitated because in the Reply Brief, Appellants would like to include the rejection of claims 29 and 49-51 under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US 6,143,530) in view of Calos (US 6,632,672), Hartley et al. (US 5,888,732) and Christ & Droge (J. Mol. Biol. 288:825-836, 1999) under review on appeal. This rejection was not presented for review in the appellant's brief dated 05/21/08.

**(1) Real Party in Interest**

A statement identifying by name the real party in interest is contained in the brief.

**(2) Related Appeals and Interferences**

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

**(3) Status of Claims**

The statement of the status of claims contained in the brief is correct.

**(4) Status of Amendments After Final**

No amendment after final has been filed.

**(5) Summary of Claimed Subject Matter**

The summary of claimed subject matter contained in the brief is correct.

**(6) Grounds of Rejection to be Reviewed on Appeal**

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

**(7) Claims Appendix**

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(8) Evidence Relied Upon**

6,143,530	Crouzet et al.
5,464,764	Capecchi et al.
5,888,732	Hartley et al.
6,632,672	Calos

Lange-Gustafson et al. "Purification and properties of Int-h, a variant protein involved in site-specific recombination of bacteriophage lambda". J. Biol. Chem., vol259, no. 20 (October 25, 1984), pp. 12724-12732.

Christ et al. "Alterations in the directionality of lambda site-specific recombination catalyzed by mutant integrases in vivo". J. Mol. Biol., vol288 (May 21, 1998), pp. 825-836.

Declaration of Peter Droge under 37 C.F.R. 1.132, filed on 10/04/06.

**(9) Grounds of Rejection**

The following ground(s) of rejection are applicable to the appealed claims:

(a) *Claims 29-30, 32-33, 36, 38, 44-48 and 58 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999).*

Crouzet et al teach a method for producing therapeutic DNA molecules by excision from a plasmid or from a chromosome (must be stably integrated) by site-specific recombination, wherein the site-specific recombination is carried out in a host cell or *in vitro*, and wherein the site-specific recombination is carried out by means of various systems which lead to site-specific recombination between sequences (col. 3, line 27 continues to line 20 of col. 4; Figures 1-2). Specifically, Crouzet et al disclose that the gene or genes of interest flanked by the two sequences permitting site-specific recombination, positioned in the direct orientation in a vector, a phage or a virus, and the specific recombination sequences and recombinases used can belong to different structural classes, including the integrase family of bacteriophage  $\lambda$  and the attP and attB sequences catalyzed by the phage lambda integrase (col. 4, lines 21-52; col. 5, lines 32-41). The disclosed attB sequence is identical to SEQ ID NO:1 of the present application (see SEQ ID NO:6), and therefore the corresponding attP recombination sequence must have the same SEQ ID NO: 2 of the present application, or at least a derivative thereof. Additionally, Crouzet et al. teach that their genetic constructs can

**be used for the construct of cell hosts having disclosed elements integrated in their genomes** (col. 4, lines 4-9; col. 8, lines 64; col. 9, lines 27-60; and Figure 1).

Crouzet et al further teach that the recombinase to be introduced into a host cell can be under the control of a promoter or a system of inducible promoters, and it can be carried by a plasmid, a phage or even in the non-therapeutic region of the recombinant DNAs (col. 7, line 45 continues to line 39 of col. 8), and that **any type of host cell can be used including eukaryotic cells such as yeasts, animal cells, plant cells, mammalian cells such as CHO, COS and mouse NIH3T3** (col. 9, lines 48-60).

Crouzet et al also disclose that their genetic constructs comprise one or more genes of interest such as the genes coding for enzymes, hormones, growth factors, apolipoproteins, tumor suppressor genes, suicide genes, natural or artificial immunoglobulin or an antigenic peptide (col. 13, lines 14-50).

**Crouzet et al do not specifically teach the use of any modified  $\lambda$  Integrase, specifically Int-h or Int h/218 in their method of producing therapeutic DNA molecules, even though they teach that any specific recombination sequences and appropriate recombinases can be used, including those belonging to the bacteriophage  $\lambda$  system.**

However, at the effective filing date of the present application Christ & Droge already taught the mutant  $\lambda$  Integrases, Int-h and Int-h/218, that are capable of mediating substrate deletion through  $\lambda$  site-specific recombination in prokaryotes in the absence of co-factors Fis and Xis (see at least the abstract; page 829, right hand column, top and bottom of the first full paragraph). Christ & Droge further teach that **the potential of these mutants to perform recombination in the absence of accessory factors**

is due to their enhanced affinity for core sites, and that Int-h is known to recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than wild-type Integrase (page 827, left column, second full paragraph; page 828, left column, top of last paragraph).

Accordingly, it would have been obvious for an ordinary skilled artisan to modify the method taught by Crouzet et al by utilizing specifically the mutant  $\lambda$  Integrases, Int-h and Int-h/218, of Christ & Droge in their method of producing therapeutic DNA molecules due to the advantages offered by the mutant integrases, at least the mutant Integrases can recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than the wild-type Integrase.

An ordinary skilled artisan would have been motivated to carry out the above modification because as taught by Christ & Droge, at least these mutant Integrases can recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than wild-type Integrase.

An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Crouzet et al., Christ & Droge, coupled with a high level of skill of an ordinary skilled artisan in the relevant art.

Therefore, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

(b) *Amended claims 29 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999) as applied to claims 29-30, 32-33, 36, 38, 44-48 and 58 above, and further in view of Capecchi et al. (US 5,464,764).*

The teachings of Crouzet et al. and Christ & Droge have been discussed above. However, neither Crouzet et al nor Christ & Droge teach that the first and/or the second DNA segment further comprising a sequence effecting integration of said first and/or second DNA segment into the genome of a cell by homologous recombination, even though Crouzet et al teach specifically that the genetic constructs can be used for the construct of cell hosts having disclosed elements integrated in their genomes and that the insertion may also be carried out by homologous recombination (col. 4, lines 4-9; col. 8, lines 60-64; and Figure 1).

However, at the effective filing date of the present application Capecchi et al. already describe a well-known method and a positive-negative selector vectors comprising sequences to be introduced in the genome of a target cell by the homologous recombination approach (see abstract and Figure 1).

It would have been obvious for an ordinary skilled artisan to further modify the modified method of Crouzet et al and Christ & Droge by introducing the genetic construct in the form of a positive-negative selector vector described by Capecchi et al. into a target host cell capable of homologous recombination to incorporate their genetic construct in the genome of the host cell as specifically taught by Crouzet et al.



An ordinary skilled artisan would have been motivated to carry out the above modification because the approach taught by Capecchi et al. overcomes many problems associated with random integration, and that the gene of interest can be introduced into any predetermined region of the genome of a target host cell.

An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Crouzet et al., Christ & Droge and Capecchi et al, coupled with a high level of skill of an ordinary skilled artisan in the relevant art.

Therefore, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

(c) *Amended claims 29, 34-35, 36-37 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999) as applied to claims 29-30, 32-33, 36, 38, 44-48 and 58 above, and further in view of Hartley et al. (US 5,888,732).*

The teachings of Crouzet et al. and Christ & Droge have been discussed above. However, neither Crouzet et al nor Christ & Droge teach that the first DNA segment stably integrated into the genome of a eukaryotic cell comprising an attL sequence according to SEQ ID NO:3 or a derivative thereof, or an attR sequence according to SEQ ID NO:4 or a derivative thereof, even though Crouzet et al teach specifically that a method for producing therapeutic DNA molecules by excision from a plasmid or from a chromosome (must be stably integrated) by site-specific recombination, wherein the

site-specific recombination is carried out in a host cell or *in vitro*, and wherein the site-specific recombination is carried out by means of various systems which lead to site-specific recombination between sequences, including the use of bacteriophage  $\lambda$  and the attP and attB sequences (col. 3, line 27 continues to line 20 of col. 4; Figures 1-2).

However, at the effective filing date of the present application Hartley et al already taught both *in vitro* and *in vivo* (e.g., in eukaryotic host cells) methods for the exchange of DNA segments through the use of various recombination proteins described in the art, including  $\lambda$  Integrase (see at least Summary of the Invention; col. 13, lines 35-55 and line 57 continues to line 24 of col. 16) and its recognition sequences including attB, attP, attL, and attR sequences (col. 8, lines 43-63). The disclosed attL and attR recombination sequences that are catalyzed by  $\lambda$  Integrase taught by Hartley et al. must have the same SEQ ID NO:3 and SEQ ID NO:4, respectively, or at least a derivative thereof. Hartley et al. also teach the use of integrase in the presence of  $\lambda$  protein Xis (excise) to catalyze the reaction of attR and attL (col. 15, lines 1-3). Hartley et al. also teach engineered att recombination sites having one or multiple mutations to enhance specificity or efficiency of the recombination reaction, and that a tripartite protein fusion could be accomplished with parental plasmids containing recombination sites attR1 and attR2; attL1 and attL3; and attR3 and attL2 (col. 16, lines 26-61; col. 17, line 47 continues to line 46 of col. 18).

It would have been obvious for an ordinary skilled artisan to modify the method of Crouzet et al and Christ & Droge by also utilizing the  $\lambda$  Integrase recognition sequences attL and attR sequences flanking the gene or genes of interest, optionally along with a

source of Xis factor under the control of a promoter or a system of inducible promoters, for the production of therapeutic DNA molecules. Once again, it is noted that Crouzet et al teach specifically that the site-specific recombination is carried by means of various systems which lead to site-specific recombination between sequences.

An ordinary skilled artisan would have been motivated to carry out the above modification because the excision system involving  $\lambda$  Integrase and its recognition sites attL and attR sequences is well known and already taught by Hartley et al for the exchange of DNA segment in both *in vitro* and *in vivo*.

An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Crouzet et al., Christ & Droge and Hartley et al, coupled with a high level of skill of an ordinary skilled artisan in the relevant art.

Therefore, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

(d) *Claims 29 and 49-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Calos (US 6,632,672), Hartley et al. (US 5,888,732) and Christ & Droge (J. Mol. Biol. 288:825-836, 1999; IDS).*

Crouzet et al teach a method for producing therapeutic DNA molecules by excision from a plasmid or from a chromosome (integrated into a cellular genome) by site-specific recombination, wherein the site-specific recombination is carried out in a

host cell or *in vitro*, and wherein the site-specific recombination is carried out by means of various systems which lead to site-specific recombination between sequences (col. 3, line 27 continues to line 20 of col. 4; Figures 1-2). Specifically, Crouzet et al disclose that the gene or genes of interest flanked by the two sequences permitting site-specific recombination, positioned in the direct orientation in a vector, a phage or a virus, and the specific recombination sequences and recombinases used can belong to different structural classes, including the integrase family of bacteriophage  $\lambda$  and the preferred attP and attB sequences catalyzed by the phage lambda integrase (col. 4, lines 21-52; col. 5, lines 32-41). The disclosed attB sequence is identical to SEQ ID NO:1 of the present application (see SEQ ID NO:6), and therefore the corresponding attP recombination sequence must have the same SEQ ID NO: 2 of the present application, or at least a derivative thereof. Additionally, Crouzet et al. teach that their genetic constructs can be used for the construct of cell hosts having disclosed elements integrated in their genomes (col. 4, lines 4-9; col. 8, lines 64; col. 9, lines 27-60; and Figure 1). Crouzet et al further teach that the recombinase to be introduced into a host cell can be under the control of a promoter or a system of inducible promoters, and it can be carried by a plasmid, a phage or even in the non-therapeutic region of the recombinant DNAs (col. 7, line 45 continues to line 39 of col. 8), and that any type of host cell can be used including eukaryotic cells such as yeasts, animal cells, plant cells, mammalian cells such as CHO, COS and mouse NIH3T3 (col. 9, lines 48-60). Crouzet et al also disclose that their genetic constructs comprise one or more genes of interest such as the genes coding for enzymes, hormones, growth factors,

apolipoproteins, tumor suppressor genes, suicide genes, natural or artificial immunoglobulin or an antigenic peptide (col. 13, lines 14-50).

Crouzet et al do not teach specifically how the therapeutic DNA molecules are integrated in a eukaryotic cellular genome to be excised later by site-specific recombination, particularly the use of any modified  $\lambda$  Integrase (e.g., Int-h or Int h/218) even though they teach that any specific recombination sequences and appropriate recombinases can be used, including those belonging to the bacteriophage  $\lambda$  system; or the process involving performing a second sequence specific recombination of DNA by Int-h or Int-h/218 and a Xis factor.

However, at the effective filing date of the present application Calos already taught a method of specifically integrating a polynucleotide sequence of interest in a genome of a eukaryotic cell (yeasts, mammalian host cells) using a targeting construct comprising a i) first recombination site and a polynucleotide sequence of interest, and ii) a site-specific recombinase, and the genome of the eukaryotic cell comprises a second recombination wherein recombination between the first and second recombination sites is facilitated by the site-specific recombinase, based in part on the discovery that there exist in various eukaryotic genomes specific nucleic acid sequences (pseudo-recombination sequences) that may be distinct from wild-type recombination sequences and that can be recognized by a site specific recombinase (see at least the abstract; col. 13, line 60 continues to line 16 of col. 14; col. 23, line 10 continues to line 18 of col. 24). Calos et al further disclosed that the used site-specific recombinase encompasses Cre,  $\lambda$  integrase and others (col. 7, lines 33-43; col. 14, lines 17-45); and that either

wild-type attB or wild-type attP sequence can be used in the targeting construct (col. 18, line 58 continues to line 54 of col. 19).

Additionally, at the effective filing date of the present application Hartley et al also taught both *in vitro* and *in vivo* (e.g., in eukaryotic host cells) methods for the exchange of DNA segments through the use of various recombination proteins described in the art, including  $\lambda$  Integrase (see at least Summary of the Invention; col. 13, lines 35-55 and line 57 continues to line 24 of col. 16) and its recognition sequences including attB, attP, attL, and attR sequences (col. 8, lines 43-63). Hartley et al. disclosed that integrative recombination involves the Int and IHF proteins and sites attP and attB, and recombination results in the formation of two new sites attL and attR; while excisive recombination requires Int, IHF, and Xis, and sites attL and attR to generate att P and attB (col. 14, line 13 continues to line 4 of col. 15). Hartley et al. also taught engineered att recombination sites having one or multiple mutations to enhance specificity or efficiency of the recombination reaction, and that a tripartite protein fusion could be accomplished with parental plasmids containing recombination sites attR1 and attR2; attL1 and attL3; and attR3 and attL2 (col. 16, lines 26-61; col. 17, line 47 continues to line 46 of col. 18).

Furthermore, Christ & Droge also taught the mutant  $\lambda$  Integrases, Int-h and Int-h/218, that are capable of mediating substrate deletion through  $\lambda$  site-specific recombination in prokaryotes in the absence of co-factors Fis and Xis (see at least the abstract; page 829, right hand column, top and bottom of the first full paragraph). Christ & Droge further teach that the potential of these mutants to perform recombination in

the absence of accessory factors is due to their enhanced affinity for core sites, and that Int-h is known to recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than wild-type Integrase (page 827, left column, second full paragraph; page 828, left column, top of last paragraph).

Accordingly, it would have been obvious for an ordinary skilled artisan to modify the method taught by Crouzet et al by using a eukaryotic cell host whose genome comprises an integrated expression cassette containing a gene(s) of interest flanked by the two sequences permitting site-specific recombination such as attL and attR as a result of integrating a targeting construct containing either wild-type attB or wild-type attP sequence as the first recombination site and a gene(s) of interest into the eukaryotic host cell whose genome already containing either pseudo attP or pseudo attB, respectively, in light of the teachings of Calos; and the subsequent release of the integrated expression cassette containing a gene(s) of interest from these recombinant eukaryotic hosts by a second recombination in the presence of a Xis factor, including the Xis factor under the control of a promoter or a system of inducible promoters, and the used recombinases are  $\lambda$  Integrase mutants Int-h and Int-h/218 in light of the teachings of Hartley et al. and Christ & Droge as discussed above.

An ordinary skilled artisan would have been motivated to carry out the above modifications because at least the method of site-specifically integrating a polynucleotide sequence of interest in a genome of a eukaryotic cell using a site-specific recombinase has been well established by Calos, along with the well-characterized  $\lambda$  Integrase recombinase system used for exchange DNA segments in

both *in vitro* and *in vivo* as taught by Hartley et al. Additionally, Christ & Droge taught at least that the mutant  $\lambda$  Integrases, Int-h and Int-h/218, can recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than wild-type  $\lambda$  Integrase, particularly suitable for performing recombinations between wild-type att sites and corresponding pseudo att sites. Similar to the expression of the recombinase under the control of a promoter or a system of inducible promoters, the expression of the X factor under the control of a system of inducible promoter is also highly desirable for a better regulation of the excision reaction in the recombinant eukaryotic host cells.

An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Crouzet et al., Calos, Hartley et al., and Christ & Droge, coupled with a high level of skill of an ordinary skilled artisan in the relevant art.

Therefore, the claimed invention as a whole was *prima facie* obvious in the absence of evidence to the contrary.

#### **(10) Response to Argument**

(a) *Response to arguments for the rejection of claims 29-30, 32-33, 36, 38, 44-48 and 58 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999).*

1. Appellant argues that Crouzet et al worked with wild-type integrases in eukaryotic cells, while Christ & Droge worked in prokaryotic systems with mutant



intergrases; and it is Appellant's position that there was no a priori expectation of success even if motivation for combining these two very distinct systems were presumed. Appellant also argue that the examiner's argument rests solely upon the alleged statement that "the conditions required by wild-type lambda integrase to mediate recombination actions in prokaryotic cells, under physiological conditions and in vitro conditions are apparently more stringent than those required by Int-h...", and that this evidence is supposed supported by Hartley et al, Christ & Droge and Lange-Gustafson et al. With respect to the Hartley et al reference, Appellant argues that this reference makes no mention of modified integrases and therefore it is impossible for Hartley to provide any comparative statement about the stringency of a modified int's activity relative to that of wild-type lambda integrases. With respect to the Lange-Gustafson et al reference, Appellant argues that considering the data of Lange-Gustafson that allegedly show that Int-h works better with supercoiled DNA, it undercuts the relevance of this reference. Additionally, Appellants argues that the studies in the reference were performed in vitro and reflect conditions that have nothing to do with the environment inside a living eukaryotic cell. With respect to the Christ & Droge reference, Appellant argues that the work reported in this reference on modified integrases was all performed in prokaryotic cells and whatever the requirements observed in such prokaryotic cells can not be extrapolated to the activity in eukaryotic cells.

With respect to the main issue whether the modified integrases Int-h and Int-h/218 would work in eukaryotic cells, based on the teachings of cited prior art of Hartley

et al, Christ & Droge and Lange-Gustafson et al an ordinary skilled artisan would reasonably expect at least Int-h or both Int-h and Int-h/218 to function in eukaryotic cells for the following reasons:

(i) Although the Hartley et al reference does not mention Int-h or Int-h/218, the reference teaches clearly that wild-type  $\lambda$  integrase is capable of mediating the exchange of DNA fragments in both *in vitro* and *in vivo* in cells including both eukaryotic and prokaryotic cells (col. 13, lines 35-55), regardless whether the DNA is negative supercoiled (prokaryotic cell genome) or relaxed (eukaryotic genome). Moreover, Hartley et al disclose specifically that wild-type  $\lambda$  Integrase requires accessory factors such as IHF protein for integrative recombination and IHF and Xis proteins for excisive recombination (col. 14, line 26 continues to line 4 of col. 15). It should be noted the same basic teachings are taught in the primary reference of Crouzet et al.

(ii) Lange-Gustafson et al already stated "In contrast to the wild-type int gene product (Int+), which produces almost no recombinants in the absence of IHF, purified Int-h protein sponsors reduced but significant levels of integrative recombination in the absence of any *E. Coli* supplement. This shows that the int gene encodes all the information necessary for the elementary steps in recombination and implies that IHF functions as an accessory protein" (first paragraph of the abstract); "When supplemented by IHF, recombination promoted by Int-h resembles that promoted by Int+ in kinetics, stoichiometry of Int and IHF, and nature of the recombinant product. Under these conditions, Int-h uses

supercoiled DNA more effectively than nonsupercoiled DNA as a substrate for recombination, as does Int+. However, in the absence of IHF, Int-h recombines supercoiled and nonsupercoiled substrates identically, indicating that IHF is an important part of the mechanism that senses the supercoiled state of the substrate DNA during recombination" (top of second paragraph of the abstract). These statements do not undercut the examiner's position in any shape or form as argued by Appellant. Only when supplemented by IHF, Int-h uses supercoiled DNA more effectively than nonsupercoiled DNA. This does not mean that under this specific condition, Int-h would not mediate recombination with nonsupercoiled DNA. Moreover, Lange-Gustafson et al also disclose specifically that in the absence of IHF, Int-h recombines supercoiled and nonsupercoiled substrates identically. Thus, the recombination activity of Int-h is not dependent on the supercoiled and/or relaxed state of a DNA substrate. This is also supported by the statement "the int gene encodes all the information necessary for the elementary steps in recombination".

(iii) Although Christ & Droge did not perform site-specific recombination in eukaryotic cells, they teach specifically that the mutant  $\lambda$  Integrases, Int-h and Int-h/218, are capable of mediating substrate deletion through  $\lambda$  site-specific recombination in prokaryotes in the absence of co-factors Fis and Xis (see at least the abstract; page 829, right hand column, top and bottom of the first full paragraph). Christ & Droge further teach that the potential of these mutants to perform recombination in the absence of accessory factors is due to their enhanced affinity for core sites, and that Int-h is known to recombine pairs of att sites which differ in their overlap

**sequence by one or more base-pairs more efficiently than wild-type Integrase** (page 827, left column, second full paragraph; page 828, left column, top of last paragraph). Moreover, Table 1 also indicates clearly in contrast to Int-h or Int-h/218, **wild-type Int usually requires an accessory IHF for inversion and/or deletion reactions.**

Accordingly, based on the analysis of the state of the prior art at least through the teachings of Crouzet et al., Hartley et al., Lange-Gustafson et al., and Christ & Droge as discussed above, **an ordinary skilled artisan would reasonably expect at least Int-h or both Int-h and Int-h/218 to function in eukaryotic cells. It is also abundantly clear that the conditions that are required by a wild-type  $\lambda$  integrase to mediate recombination in prokaryotic cells, in vitro conditions and in vivo are more stringent than those required by the Int-h or Int-h/218 (without the requirement of accessory factors).** With respect to the motivation for combining the teachings of Crouzet et al and Christ & Droge, as already noted in the above rejection, an ordinary skilled artisan would have been motivated to modify the method taught by Crouzet et al by utilizing specifically the mutant  $\lambda$  Integrases, Int-h and Int-h/218, of Christ & Droge in their method of producing therapeutic DNA molecules due to the advantages offered by the mutant integrases, at least the mutant Integrases can recombine pairs of att sites which differ in their overlap sequence by one or more base-pairs more efficiently than the wild-type Integrase.

2. Appellant further argues that the examiner has dismissed evidence provided by Appellant in the form of the Rule 132 declaration (Exhibit 6). In the

Declaration, Dr. Droge explained that the skilled artisan could not predict the success of using modified integrases in eukaryotic cells for the simple reason that it is well known that the organization of the prokaryotic genome is distinct from eukaryotics. In the Declaration, Appellant stated "However, one has to realize that DNA substrates (whether episomal or genomic) are negatively supercoiled inside *E. coli*. It was, therefore, not obvious to one of ordinary skill to deduce from the existing data that the mutant recombinase would work inside mammalian cells where the DNA is topologically relaxed" (page 2, lines 9-12 of paragraph numbered 3). In this Appeal Brief, Appellant stated "Without the aid of topologically underwound DNA, which exists only in prokaryotic cells, it was reasonable to assume that mutant Int proteins cannot function" (page 7, lines 4-5). Appellant further argues that the only fact of record supports appellant's position regarding unpredictability and that alone is sufficient to undercut the examiner's position. The basis premise for the rejection that one can assume that modified integrase will operate in eukaryotic cells based on their performance in prokaryotic cells is flawed as a matter of scientific principle because it could very well have been the case that what made them allegedly work "better" in prokaryotic cells, as compared to wild-type integrase, would have worked against them in the context of eukaryotic cells.

(i) The Examiner has considered fully the Declaration filed under 37 CFR 1.132, filed on 10/04/06 but it was not found persuasive to overcome the rejection of record. Initially, the Examiner would like to note that the cited paragraphs in the Declaration and in this Appeal Brief appear to be contradictory. While the Declaration

states that the DNA substrates are negatively supercoiled inside *E. coli* while the DNA inside mammalian cells is topologically relaxed, Appellant states in this Appeal Brief that without the aid of topologically underwound DNA (implying relaxed DNA?), which exists only in prokaryotic cells, it was reasonable to assume that mutant Int proteins can not function.

(ii) Nevertheless, since wild-type lambda integrases are capable of mediating sequence specific recombination events in both eukaryotic (DNA substrates are topologically relaxed) and prokaryotic cells (DNA substrates are negatively supercoiled), and it is known in the prior art that the conditions required by a wild-type lambda integrase to mediate recombination reactions in prokaryotic cells, under physiological conditions and *in vitro* conditions are apparently more stringent than those required by the Int-h as evidenced at least by the teachings of Hartley et al., Christ & Droge and Lange-Gustafson et al as elaborated in more details above, it is therefore entirely reasonable for an ordinary skilled artisan to expect that at least Int-h or both Int-h and Int-h/218 are able to function in eukaryotic cells. Particularly, Lange-Gustafson et al already disclosed specifically that in the absence of IHF, Int-h recombines supercoiled and nonsupercoiled substrates identically; and that the recombination activity of Int-h is not dependent on the supercoiled and/or relaxed state of a DNA substrate (activities under conditions with/without the presence of IHF). Appellant's arguments relating the unpredictability are not consistent with the state and the teachings of the prior art at least reflected through the teachings

**of Crouzet et al., Hartley et al., Lange-Gustafson et al., and Christ & Droge as discussed above.**

(iii) It also appears that Appellant requires the Examiner to support his position or conclusions with a prior art that teaches explicitly the use of Int-h or Int-h/218 to carry out sequence specific recombination of DNA in a eukaryotic cell. However, it is noted that if such a reference exists, the reference would be qualified and used for a rejection under 35 U.S.C 102.

*(b) Response to arguments for the rejection of claims 29 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999) as applied to claims 29-30, 32-33, 36, 38, 44-48 and 58 above, and further in view of Capecchi et al. (US 5,464,764).*

Appellant argues basically that Capecchi et al reference fails to address the issue whether modified integrases would work in eukaryotic cells as already set forth above. Appellant also argues that there was no motivation for combining the primary and secondary references, and even if there were, there was no likelihood of success that they would work together.

Please refer to the same Examiner's response to Appellant' arguments on the lack of motivation and the lack of an expectation of success for combining the Crouzet et al. and Christ & Droge references in the rejection of claims 29-30, 32-33, 36, 38, 44-48 and 58 above. The teachings of Capecchi et al were used to supplement the

combined teachings of Crouzet et al. and Christ & Droge on the limitation recited in dependent claim 43.

*(c) Response to arguments for the rejection of claims 29, 34-35, 36-37 and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Christ & Droge (J. Mol. Biol. 288:825-836, 1999) as applied to claims 29-30, 32-33, 36, 38, 44-48 and 58 above, and further in view of Hartley et al. (US 5,888,732).*

Once again, Appellant argues basically that Hartley et al reference fails to address the issue whether modified integrases would work in eukaryotic cells as already set forth above because the reference teaches recombinational methods in prokaryotic and eukaryotic cells using exclusively the wild-type lambda integrase; and fails to address the issue whether modified integrases would work in eukaryotic cells. Appellant also argues that there was no motivation for combining the primary and secondary references, and even if there were, there was no likelihood of success that they would work together.

Please refer to the same Examiner's response to Appellant' arguments on the lack of motivation and the lack of an expectation of success for combining the Crouzet et al. and Christ & Droge references in the rejection of claims 29-30, 32-33, 36, 38, 44-48 and 58 above. The teachings of Hartley et al were used primarily to supplement the combined teachings of Crouzet et al. and Christ & Droge on limitations recited in dependent claims 34-35, 37 and 39.



*(d) Response to arguments for the rejection of claims 29 and 49-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crouzet et al. (US Patent 6,143,530) in view of Calos (US 6,632,672), Hartley et al. (US 5,888,732) and Christ & Droge (J. Mol. Biol. 288:825-836, 1999; IDS).*

Appellants argue basically that the teachings of Calos can not cure the deficiencies pointed out for the Crouzet, Hartley and Christ & Droge references as discussed above.

Once again, please refer to the same Examiner's response to Appellant's arguments on the defects of the Crouzet, Hartley and Christ & Droge references as discussed above.

*(e) Additional arguments presented in the Reply Brief under the context of general discussion of the references.*

1. With respect to the Crouzet et al reference, Appellants further argue that the reference has no proof or examples showing that lambda integrase would actually work in eukaryotes, much less whether one would have to provide accessory factors, and whether the yields and quality would be sufficient. The Crouzet et al reference's inclusion of any and all type of cell host, especially mammalian animal cells, is prophetic and completely unsupported from a scientific standpoint.

Please note that the teachings of the Crouzet et al reference are not limited to the production of mini-circles only in bacteria. Please see **at least issued claims 29-32, 34-39, particularly claims 32 and 29 wherein the host cell is specifically recited to be eukaryotic cell and wherein one or more copies of the recombinant DNA is inserted into the genome of the cultured host cell, respectively.** Additionally, please note that issued claims of a US patent are considered to be valid until they are invalidated, and that these issued claims have been considered for various issues including enablement issues under the Wands factors. Furthermore, Calos (US 6,632,672) already showed at least **an exemplified phage recombinase  $\phi$ C31 integrase to be capable of carrying out site-specific integration in both *E.Coli* and in mammalian cells** (see examples 6-7), and taught that **a well known phage Cre recombinase, within the same Integrase subfamily as the  $\lambda$  integrase, directs site-specific recombination in both yeasts and mammalian cells** (col. 2, lines 27-36; col. 7, lines 34-43).

2. With respect to the Capecchi et al reference, Appellants argue that the reference neither teach the use of site-specific recombination in eukaryotes nor a combined approach of homologous recombination and site-specific recombination; and therefore the deficiencies of the Crouzet et al reference remain.

The teachings of Capecchi et al were used primarily to supplement the combined teachings of Crouzet et al. and Christ & Droge on the limitation recited in dependent claim 43.

3. With respect to the Hartley et al reference, once again Appellants argue that the reference do not teach site-specific recombinations in eukaryotic cells, and only showed the actual recombination reaction to be performed *in vitro*.

Please see at least the issued claims of US patent 6,143,530 to Crouzet et al. Additionally, there is no requirement that a patent has to disclose every working example to be enabled. The teachings of Hartley et al were used primarily to supplement the combined teachings of Crouzet et al. and Christ & Droge on limitations recited in dependent claims 34-35, 37 and 39.

4. With respect to the Christ & Droge reference, Appellants argue that the reference do not teach site-specific recombinations in eukaryotic cells; and in contrast to bacteria in which genomic or plasmid DNA is negatively supercoiled, DNA in the nucleus of eukaryotes is organized in form of chromatin. Appellants further argued that it was also unclear that the mutant recombinases would even be transported into the nucleus, or that they would have any biological activity or stability once in the nucleus because the physiological conditions in a nucleus are different to the physiology in a bacterium or an *in vitro* system.

Once again, please see at least issued claims 29-32, 34-39 of US patent 6,143,530 to Crouzet et al., particularly claims 32 and 29 wherein the host cell is specifically recited to be eukaryotic cell and wherein one or more copies of the recombinant DNA is inserted into the genome of the cultured host cell, respectively. Furthermore, Calos (US 6,632,672) already showed at least an exemplified phage recombinase  $\phi$ C31 integrase being capable of carrying out

site-specific integration in both *E.Coli* and in mammalian cells (see examples 6-7), and taught that a well known phage Cre recombinase, within the same Integrase subfamily as the  $\lambda$  integrase, directs site-specific recombination in both yeasts and mammalian cells (col. 2, lines 27-36; col. 7, lines 34-43).

The teachings of Christ & Droge were used primarily to supplement the teachings of Crouzet et al on the specific use of the modified Integrases namely Int-h and Int-h/218. As already discussed above, since wild-type lambda integrases are capable of mediating sequence specific recombination events in both eukaryotic (DNA substrates are topologically relaxed) and prokaryotic cells (DNA substrates are negatively supercoiled), and it is known in the prior art that the conditions required by a wild-type lambda integrase to mediate recombination reactions in prokaryotic cells, under physiological conditions and *in vitro* conditions are apparently more stringent than those required by the Int-h as evidenced at least by the teachings of Hartley et al., Christ & Droge and Lange-Gustafson et al, it is therefore entirely reasonable for an ordinary skilled artisan to expect that at least Int-h or both Int-h and Int-h/218 are able to function in eukaryotic cells. Particularly, Lange-Gustafson et al already disclosed specifically that in the absence of IHF, Int-h recombines supercoiled and nonsupercoiled substrates identically; and that the recombination activity of Int-h is not dependent on the supercoiled and/or relaxed state of a DNA substrate (activities under conditions with/without the presence of IHF). Furthermore, the examiner would like to note that the DNA segment comprising an att site that is integrated into the genome of a eukaryotic cell to be used in the method as claimed can

**be originated or originally derived from a plasmid DNA** that was introduced into the eukaryotic cell.

**(11) Related Proceeding(s) Appendix**

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

/QUANG NGUYEN/  
Primary Examiner, Art Unit 1633

/George C. Elliott, Ph.D./  
Director, Technology Center 1600

**Conferees:**

/Joseph T. Woitach/  
Supervisory Patent Examiner, Art Unit 1633

/Ram R. Shukla/  
Supervisory Patent Examiner, Art Unit 1634